HOUSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced that it will release fiscal 2025 first quarter results before the ...

Stephen T. Dickinson (they/them), a project manager at the Urban Health Collaborative within the Dornsife School of Public Health at Drexel. Dr. Dickinson presented research findings from their MCRC ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $41.00. Silvan Tuerkcan has given his Buy rating due to a ...

Data from the phase 3 BREAKWATER trial (NCT04607421), presented at the 2025 Gastrointestinal Cancers Symposium, demonstrated that combining encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6 ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

IES Holdings, Inc. HOUSTON, Jan. 22, 2025 (GLOBE NEWSWIRE) -- IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced that it has amended and restated its existing ...

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with metastatic colorectal cancer (mCRC). The authorisation is intended for ...

Credit: mi_viri/Shutterstock. Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with metastatic colorectal cancer (mCRC). The ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

TORONTO, Jan. 20, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for FRUZAQLA ™ (fruquintinib capsules), indicated for the ...